VR Plus Neurostimulation Just Cleared a Major Feasibility Hurdle. Now Comes the Hard Part.
A Nature Medicine feasibility trial combining immersive VR with synchronous neurostimulation hit enrollment and kinematic endpoints in stroke rehab....
What Icon’s $300M Microsoft Bet Means for the Sites Running Their Trials
Icon's enterprise-wide Microsoft Copilot deployment and $300M AI investment will reshape how CRAs monitor, query, and escalate — here's...
Benchmark Scores Don’t Break. Clinical Reality Does. The Health AI Readiness Illusion.
Nature Medicine's frontier AI evaluation exposes a dangerous gap: models acing medical benchmarks collapse under adversarial pressure, and the...
Ipsen Acquires Kartos Therapeutics for $450M to Develop Navtemadlin for Myelofibrosis
Ipsen acquires Kartos for navtemadlin for myelofibrosis, an MDM2 inhibitor designed to help ruxolitinib non-responders. Phase III data expected...
Infigratinib Shows +2.1 cm/year Height Gain in Achondroplasia Trial
Infigratinib achondroplasia trial shows 2.1 cm/year height gain over placebo, with first-ever statistically significant body proportionality improvements in Pha
What the MASAI Trial Correspondence in The Lancet Actually Says About AI Screening Evidence
The Lancet correspondence on the MASAI trial exposes a core evidentiary gap: AI mammography's performance gains rest on intermediate...
What a 26-Trial Ketamine Meta-Analysis Gets Right, and What It Still Can’t Capture
A JAMA Psychiatry meta-analysis of 26 RCTs confirms ketamine's acute antidepressant effect. Here's what 1,166 trial patients don't show...
Medicenna’s MDNA11 Shows 30-40% Response Rates in Checkpoint-Resistant Cancers
Medicenna's MDNA11 shows 30-40% response rates in checkpoint-resistant cancers, with Phase 1/2 data expected in Q4 2026.
J&J presents nipocalimab data showing benefits in early-stage myasthenia gravis
J&J's nipocalimab showed significant functional improvements in early-stage myasthenia gravis patients, with benefits sustained through infections.
FDA Approves Risankizumab for Pediatric Psoriasis and Psoriatic Arthritis
FDA approves risankizumab for pediatric psoriasis and psoriatic arthritis in children six years and older, expanding treatment options for...